US4131971040
© BusinessWire
08.12.2025
HRMY
LISTED
NASDAQ
Harmony Biosciences Presents Clinically Meaningful Open-Label Extension Study Effectiveness Data for EPX-100 in Dravet Syndrome
News Preview
Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced the presentation of initial open-label extension (OLE) data from the company’s ongoing Phase 3 ARGUS trial investigating EPX-100 (clemizole hydrochloride) for the treatment of Dravet syndrome (DS), which showed clinically meaningful reductions in seizure activity in participants wi...
Themefolio
Profiler
Peergroup
© BusinessWire
02.12.2025
HRMY
LISTED
NASDAQ
Harmony Biosciences to Present New Open-Label Extension Data from Phase 3 ARGUS Trial at the 2025 American Epilepsy Society Annual Meeting
News Preview
Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced that it will highlight new open-label extension data from the company’s investigation of EPX-100 (clemizole hydrochloride) in the ongoing Phase 3 ARGUS trial for the treatment of Dravet syndrome at the 2025 American Epilepsy Society (AES) Annual Meeting being held December 5 – Dece...
Themefolio
Profiler
Peergroup
© BusinessWire
24.11.2025
HRMY
LISTED
NASDAQ
Harmony Biosciences Announces Positive Results From the Pivotal Bioequivalence Study for Pitolisant Gastro-Resistant Formulation
News Preview
Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced positive results from its pivotal bioequivalence (BE) study evaluating pitolisant gastro-resistant (GR) formulation. With positive findings from both the pivotal BE and dosing optimization studies, Harmony is on track to submit a New Drug Application (NDA) for pitolisant GR in early...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Leerverkaufsstatistiken, Hedge-Fund Aktivitäten und viele weitere nutzerwertige Informationen benutzerfreundlich aufbereitet
© BusinessWire
19.11.2025
HRMY
LISTED
NASDAQ
Harmony Biosciences Announces Initiation of First-In-Human Study With Potential Best-In-Class Orexin 2 Receptor Agonist (BP1.15205) for Central Disorders of Hypersomnolence
News Preview
Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced dosing of the first participant in a Phase 1 clinical trial of BP1.15205, an investigational, potentially best-in-class, orexin 2 receptor (OX2R) agonist being developed for the treatment of narcolepsy, idiopathic hypersomnia and other central disorders of hypersomnolence. The Phase...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© BusinessWire
18.11.2025
HRMY
LISTED
NASDAQ
Harmony Biosciences to Participate in Upcoming Investor Conferences
News Preview
Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced that Harmony's management team will participate in the following upcoming investor conferences.
Citi's 2025 Global Healthcare Conference
Location: Miami, FL
Tuesday, December 2, 2025
8th Annual Evercore Healthcare Conference
Location: Miami, FL
Fireside Chat: Tue...
Themefolio
Profiler
Peergroup
© BusinessWire
04.11.2025
HRMY
LISTED
NASDAQ
Harmony Biosciences Reports Strong Q3 2025 Financial Results; Recently Raised 2025 Revenue Guidance to $845-$865M
News Preview
Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced earnings of $239.5M for Q3 2025, representing 29% year-over-year revenue growth for WAKIX®. These results were driven by the highest ever increase in average number of patients of approximately 500 for the quarter, accelerating the trajectory toward blockbuster status for WAKIX in n...
Themefolio
Profiler
Peergroup
© BusinessWire
23.10.2025
HRMY
LISTED
NASDAQ
Harmony Biosciences Preannounces Strong Q3 2025 WAKIX Performance; Raises 2025 Revenue Guidance
News Preview
Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced preliminary results for Q3 2025, highlighted by the following:
WAKIX® (pitolisant) franchise delivered net revenue of approximately $239M in Q3 2025, representing 29% year-over-year revenue growth
These results were driven by the highest ever quarterly increase in average numb...
Themefolio
Profiler
Peergroup
© BusinessWire
24.09.2025
HRMY
LISTED
NASDAQ
Harmony Biosciences Provides Update From Its Phase 3 RECONNECT Study of ZYN002 in Fragile X Syndrome
News Preview
Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced topline results from its Phase 3 registrational clinical trial (the RECONNECT Study) of ZYN002 in Fragile X syndrome (FXS). The RECONNECT Study did not meet the primary endpoint of improvement in social avoidance primarily due to a higher than expected placebo response rate.
Kuma...
Themefolio
Profiler
Peergroup
© BusinessWire
26.08.2025
HRMY
LISTED
NASDAQ
Harmony Biosciences to Present Rare Epilepsy Data at the 36th International Epilepsy Congress
News Preview
Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced that it will present data from its rare epilepsy pipeline at the 36th International Epilepsy Congress (IEC) being held August 30 – September 3, 2025, at the Lisbon Congress Centre in Lisbon, Portugal.
Poster presentations will highlight information from the company’s investigatio...
Themefolio
Profiler
Peergroup
© BusinessWire
21.08.2025
HRMY
LISTED
NASDAQ
Harmony Biosciences to Participate in 2025 Cantor Global Healthcare Conference
News Preview
Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced that Harmony's management team will participate in a fireside chat at the 2025 Cantor Global Healthcare Conference in New York, N.Y., on Thursday, September 4, 2025, at 2:10 p.m. ET.
A webcast of the fireside chat will be available on the investor page of the Harmony Biosciences...
Themefolio
Profiler
Peergroup
© BusinessWire
22.07.2025
HRMY
LISTED
NASDAQ
Harmony Biosciences to Report Second Quarter 2025 Financial Results on August 5, 2025
News Preview
Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced that it will report second quarter 2025 financial results on Tuesday, August 5, 2025, before the open of the U.S. financial markets. Harmony will host a conference call and webcast on August 5, 2025, at 8:30 a.m. ET to discuss the results.
To participate in the call, please dial 8...
Themefolio
Profiler
Peergroup
© BusinessWire
15.07.2025
HRMY
LISTED
NASDAQ
Harmony Biosciences to Participate in H.C. Wainwright "HCW@Home" Series
News Preview
Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced that Harmony's management team will participate in the virtual H.C. Wainwright "HCW@Home" series on Thursday, July 17, 2025, at 10:00 a.m. ET.
To register in advance, please use this link. A webcast of the fireside chat will be available on the investor page of the Harmony Biosci...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© BusinessWire
11.06.2025
HRMY
LISTED
NASDAQ
Harmony Biosciences Presents Preclinical Data Demonstrating Significant Wake-Promoting and Cataplexy-Suppressing Effects of BP1.15205 in Narcolepsy at SLEEP 2025
News Preview
Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced the presentation of preclinical pharmacological effect data for BP1.15205, an investigational, highly potent, and potentially best-in-class orexin 2 receptor (OX2R) agonist, which demonstrated significant wake-promoting and cataplexy-suppressing effects in a standard transgenic mous...
Themefolio
Profiler
Peergroup
© BusinessWire
05.06.2025
HRMY
LISTED
NASDAQ
Harmony Biosciences Strengthens Patent Position With Favorable Settlement in ANDA Litigation
News Preview
Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced a settlement agreement with Lupin Limited, resolving the patent infringement litigation related to Lupin’s Abbreviated New Drug Application (ANDA) for a generic version of WAKIX® (pitolisant hydrochloride). As part of the agreement, litigation in the United States District Court fo...
Themefolio
Profiler
Peergroup
© BusinessWire
04.06.2025
HRMY
LISTED
NASDAQ
Harmony Biosciences to Participate in Goldman Sachs 46th Annual Global Healthcare Conference
News Preview
Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced that Harmony's management team will participate in a fireside chat at the Goldman Sachs 46th Annual Global Healthcare Conference in Miami, FL on Monday, June 9, 2025, at 3:20 p.m., ET
A webcast of the fireside chat will be available on the investor page of the Harmony Biosciences...
Themefolio
Profiler
Peergroup
© BusinessWire
06.05.2025
HRMY
LISTED
NASDAQ
Harmony Biosciences Reports Strong Q1 2025 Financial Results, Highlights Advancement of Its Pipeline and Upcoming Catalysts, and Reaffirms 2025 Revenue Guidance
News Preview
Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced strong year-over-year revenue growth for WAKIX® of 20% in the first quarter 2025, on its way to a potential $1B+ opportunity in narcolepsy alone and poised for additional growth from its next-gen pitolisant development programs. The company has demonstrated four consecutive years of...
Themefolio
Profiler
Peergroup
© BusinessWire
29.04.2025
HRMY
LISTED
NASDAQ
Harmony Biosciences to Report First Quarter 2025 Financial Results on May 6, 2025
News Preview
Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced that it will report first quarter 2025 financial results on Tuesday, May 6, 2025, before the open of the U.S. financial markets. Harmony will host a conference call and webcast on May 6, 2025, at 8:30 a.m. ET to discuss the results.
To participate in the call, please dial 800-267-6...
Themefolio
Profiler
Peergroup
© BusinessWire
08.04.2025
HRMY
LISTED
NASDAQ
Harmony Biosciences Presents Promising Open-Label Extension Data of ZYN002 in Fragile X Syndrome
News Preview
Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced the presentation of updated data from its Open-Label Extension (OLE) study (ZYN2-CL-017) evaluating the safety and effectiveness of ZYN002 in children, adolescents, and adults with Fragile X syndrome (FXS). The data showed clinically meaningful improvements in irritability-related s...
Themefolio
Profiler
Peergroup
© BusinessWire
03.04.2025
HRMY
LISTED
NASDAQ
Harmony Biosciences Appoints Biotech Leader Ron Philip to Its Board of Directors
News Preview
Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced the appointment of Ron Philip to the Company's Board of Directors.
Ron Philip is the President and Chief Executive Officer of Orbital Therapeutics. Ron has 30 years of experience building companies, leading organizational growth, and guiding teams through the development, regulator...
Themefolio
Profiler
Peergroup
© BusinessWire
26.03.2025
HRMY
LISTED
NASDAQ
Harmony Biosciences to Participate in 24th Annual Needham Virtual Healthcare Conference
News Preview
Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced that Harmony's management team will participate in a fireside chat at the upcoming 24th Annual Needham Virtual Healthcare Conference on Wednesday, April 9, 2025, at 3:00 p.m. ET.
A webcast of the fireside chat will be available on the investor page of the Harmony Biosciences websi...
Themefolio
Profiler
Peergroup
© BusinessWire
24.03.2025
HRMY
LISTED
NASDAQ
Harmony Biosciences Names Adam Zaeske as Chief Commercial Officer to Lead the Next Phase of Commercial Growth as Its Portfolio Expands
News Preview
Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced the appointment of Adam Zaeske as Executive Vice President and Chief Commercial Officer (CCO), effective March 31, 2025. The company’s current CCO, Jeffrey Dierks, is voluntarily stepping down for personal reasons.
Zaeske brings 25 years of global leadership across the pharmaceuti...
Themefolio
Profiler
Peergroup
© BusinessWire
22.03.2025
HRMY
LISTED
NASDAQ
HRMY Investors Have Opportunity to Join Harmony Biosciences Holdings, Inc. Fraud Investigation with the Schall Law Firm
News Preview
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Harmony Biosciences Holdings, Inc. (“Harmony” or “the Company”) (NASDAQ: HRMY) for violations of the securities laws.
The investigation focuses on whether the Company issued false and/or misleading statements and...
Themefolio
Profiler
Peergroup
© BusinessWire
04.03.2025
HRMY
LISTED
NASDAQ
Harmony Biosciences to Participate in Upcoming Investor Conferences
News Preview
Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced that Harmony's management team will participate in the following upcoming investor conferences:
Barclays Global Healthcare Conference
Location: Miami, FL
Tuesday, March 11, 2025
Leerink Partners Global Healthcare Conference
Location: Miami, FL
Fireside Chat: Wednes...
Themefolio
Profiler
Peergroup
© BusinessWire
25.02.2025
HRMY
LISTED
NASDAQ
Harmony Biosciences Reports Strong 2024 Financial Results and Reiterates 2025 Net Revenue Guidance; Highlights 2025 Catalysts in Sleep/Wake and Fragile X Syndrome Development Programs
News Preview
Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced a record $201.3 million in net product revenues for the fourth quarter 2024, and full year 2024 net revenues of $714.7 million, ending the year with $576 million in cash, cash equivalents and investments on the balance sheet. The company has guided 2025 WAKIX® net revenues to $820 -...
Themefolio
Profiler
Peergroup
© BusinessWire
19.02.2025
HRMY
LISTED
NASDAQ
Harmony Biosciences Provides Update on the Status of the Supplemental New Drug Application for Pitolisant in Idiopathic Hypersomnia
News Preview
Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced that it received a Refusal to File (RTF) letter from the U.S. Food and Drug Administration (FDA) for pitolisant for the treatment of excessive daytime sleepiness (EDS) in adult patients with idiopathic hypersomnia (IH). Harmony’s 2025 net revenue guidance of $820-$860 million remain...
Themefolio
Profiler
Peergroup
© BusinessWire
18.02.2025
HRMY
LISTED
NASDAQ
Harmony Biosciences to Report Fourth Quarter and Full Year 2024 Financial Results on February 25, 2025
News Preview
Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced that it will report fourth quarter and full year 2024 financial results on Tuesday, February 25, 2025, before the open of the U.S. financial markets. Harmony will host a conference call and webcast on February 25, 2025, at 8:30 a.m. ET to discuss the results.
To participate in the...
Themefolio
Profiler
Peergroup
© BusinessWire
13.01.2025
HRMY
LISTED
NASDAQ
Harmony Biosciences Reports Strong 2024 Revenues, Provides 2025 Revenue Guidance and Highlights Key Pipeline Catalysts
News Preview
Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced strong preliminary, unaudited net product revenues for Q4 and full year 2024 of $201 million and $714 million, respectively. Building on this performance, the company is well positioned for a catalyst-rich 2025, with value-creating milestones anticipated every quarter. Harmony will...
Themefolio
Profiler
Peergroup
© PR Newswire
18.12.2024
HRMY
LISTED
NASDAQ
HARMONY BIOSCIENCES TO PRESENT AT THE 43RD ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE
News Preview
PLYMOUTH MEETING, Pa., Dec. 18, 2024 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, CA. Jeffrey M. Dayno, M.D., President and Chief Executive Officer, is scheduled to present at the conference on Wednesday, January 15, 2025...
Themefolio
Profiler
Peergroup
© PR Newswire
03.12.2024
HRMY
LISTED
NASDAQ
HARMONY BIOSCIENCES TO PARTICIPATE IN OPPENHEIMER MOVERS IN RARE DISEASE SUMMIT
News Preview
PLYMOUTH MEETING, Pa., Dec. 3, 2024 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced that Harmony's management team will participate in a fireside chat at the upcoming Oppenheimer Movers in Rare Disease Summit in New York, NY on Thursday, December 12, 2024, at 9:00 a.m. ET....
Themefolio
Profiler
Peergroup
© PR Newswire
21.11.2024
HRMY
LISTED
NASDAQ
HARMONY BIOSCIENCES TO PARTICIPATE IN UPCOMING INVESTOR CONFERENCES
News Preview
PLYMOUTH MEETING, Pa., Nov. 21, 2024 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced that Harmony's management team will participate in the following upcoming investor conferences:
Citi's 2024 Glo...
Themefolio
Profiler
Peergroup
© PR Newswire
31.10.2024
HRMY
LISTED
NASDAQ
Harmony Biosciences Holdings, Inc. Announces Pricing of Public Offering of Common Stock by Selling Shareholders
News Preview
PLYMOUTH MEETING, Pa., Oct. 30, 2024 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) (the "Company") today announced the pricing of the previously announced underwritten public offering of an aggregate of 8,000,000 shares of the Company's common stock, par value $0.00001 per share ("Common Stock"), by Marshman Fund Trust II and...
Themefolio
Profiler
Peergroup
© PR Newswire
29.10.2024
HRMY
LISTED
NASDAQ
Harmony Biosciences Holdings, Inc. Announces Commencement of Proposed Public Offering of Common Stock by Selling Shareholders
News Preview
PLYMOUTH MEETING, Pa., Oct. 29, 2024 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) (the "Company") today announced the commencement of an underwritten public offering of up to 8,000,000 shares of the Company's common stock, par value $0.00001 per share ("Common Stock"), by Marshman Fund Trust II and Valor IV Pharma Holdings, L...
Themefolio
Profiler
Peergroup
© PR Newswire
29.10.2024
HRMY
LISTED
NASDAQ
HARMONY BIOSCIENCES REPORTS STRONG THIRD QUARTER 2024 FINANCIAL RESULTS AND HIGHLIGHTS CATALYST-RICH, LATE-STAGE PIPELINE POISED TO DELIVER ONE OR MORE NEW LAUNCHES EVERY YEAR OVER NEXT FIVE YEARS
News Preview
WAKIX (pitolisant) Net Revenue of $186.0 Million for Third Quarter 2024; Surpassed $2B in Cumulative Net Revenue in Less Than Five Years
On Track to Submit sNDA for Pitolisant in Idiopathic Hypersomnia (IH) in Q4 2024 Based on Updated Strong and Sustained Efficacy Data from Long-Term Extension Study
Next-Gen Pitolisant-GR and Pitolisant-HD Prog...
Themefolio
Profiler
Peergroup
© PR Newswire
16.10.2024
HRMY
LISTED
NASDAQ
HARMONY BIOSCIENCES TO REPORT THIRD QUARTER 2024 FINANCIAL RESULTS ON OCTOBER 29, 2024
News Preview
PLYMOUTH MEETING, Pa., Oct. 16, 2024 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced that it will report third quarter 2024 financial results on Tuesday, October 29, 2024, before the open of the U.S. financial markets. Harmony will host a conference call and webcast on October 29, 2024, at 8:30 a.m. ET to discuss...
Themefolio
Profiler
Peergroup
© PR Newswire
01.10.2024
HRMY
LISTED
NASDAQ
HARMONY BIOSCIENCES HIGHLIGHTS NEW DATA, ROBUST LATE-STAGE PIPELINE WITH NEAR-TERM VALUE CREATION OPPORTUNITIES AND ITS BOLD NEW VISION AT INVESTOR DAY
News Preview
PLYMOUTH MEETING, Pa., Oct. 1, 2024 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), will be providing a comprehensive pipeline update at its Investor Day event today, showcasing new data from its orexin-2 receptor agonist, next-generation pitolisant programs, and long-term extension data from its pitolisant program in idiopathi...
Themefolio
Profiler
Peergroup
© PR Newswire
26.09.2024
HRMY
LISTED
NASDAQ
HARMONY BIOSCIENCES TO HOST FIRST INVESTOR DAY ON OCTOBER 1, 2024
News Preview
PLYMOUTH MEETING, Pa., Sept. 26, 2024 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), will provide an overview of its robust, late-stage pipeline at an in-person Investor Day at 8:30 a.m. ET on October 1 in New York City. Members of Harmony's senior leadership team along with therapeutic area key opinion leaders will present to...
Themefolio
Profiler
Peergroup
© PR Newswire
21.08.2024
HRMY
LISTED
NASDAQ
HARMONY BIOSCIENCES TO PARTICIPATE IN UPCOMING INVESTOR CONFERENCES
News Preview
PLYMOUTH MEETING, Pa., Aug. 21, 2024 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced that Harmony's management team will participate in the following upcoming investor conferences:
Wells Fargo 202...
Themefolio
Profiler
Peergroup
© Globe Newswire
06.08.2024
HRMY
LISTED
NASDAQ
Harmony Biosciences Reports Strong Second Quarter 2024 Financial Results and Advances Pitolisant High-Dose Program Toward Expected PDUFA Date in 2028
News Preview
WAKIX® (pitolisant) Net Revenue of $172.8 Million for Second Quarter 2024; ~29% Growth Year-over-Year...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
